Has Qahtan Abdulfattah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,396 in general payments to Qahtan Abdulfattah, MD across 1,033 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Qahtan Abdulfattah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Qahtan Abdulfattah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Qahtan Abdulfattah, MD

Neuromusculoskeletal Medicine, Sports Medicine · Brooksville, FLNPI 1558370411

Payments from drug & device makers

$17,396in general payments, 2019–2025

Across 1,033 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Pfizer$1K
Teva Pharmaceuticals USA, Inc.$1K
Biogen$1K
Novartis$938
Neurocrine Biosciences, Inc.$722
plus $9K from 51 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	186	$2,669
Pfizer	102	$1,477
Teva Pharmaceuticals USA, Inc.	107	$1,368
Biogen	49	$1,050
Novartis	59	$938
Neurocrine Biosciences, Inc.	39	$722
Lundbeck LLC	36	$706
Bristol Myers Squibb	38	$656
UCB, Inc.	32	$605
SK Life Science, Inc.	25	$538
EMD Serono, Inc.	26	$524
Eisai Inc.	28	$503
CSL Behring	23	$445
Sunovion Pharmaceuticals Inc.	30	$439
Genentech USA, Inc.	21	$391
Biohaven Pharmaceutical Holding Company Ltd.	23	$341
Lilly USA, LLC	17	$334
AstraZeneca(2 entities)	15	$320
Biohaven Pharmaceuticals, Inc.	21	$317
Amgen	16	$276
Johnson & Johnson(2 entities)	11	$232
Acadia Pharmaceuticals Inc	10	$204
MDD US Operations, LLC	14	$201
Sumitomo Pharma America, Inc.	11	$189
Acorda Therapeutics, Inc	11	$188
Tanabe Pharma America, Inc.	6	$135
TG Therapeutics, Inc.	6	$129
E.r. Squibb & Sons, L.L.C.	1	$117
Amneal Pharmaceuticals LLC	7	$116
Avion Pharmaceuticals	6	$116
Takeda Pharmaceuticals U.S.A., Inc.	4	$108
Sanofi	5	$95
Merz Pharmaceuticals, LLC	4	$90
Upsher-smith Laboratories LLC	4	$77
Otsuka America Pharmaceutical, Inc.	3	$72
Supernus Pharmaceuticals, Inc.	5	$63
Almatica Pharma LLC	2	$59
Kedrion Biopharma, Inc.	3	$53
Axsome Therapeutics, Inc.	2	$51
Idorsia Pharmaceuticals US Inc	2	$43
Argenx US, Inc.	2	$39
Banner Life Sciences, LLC	3	$39
Jazz Pharmaceuticals Inc.	2	$38
Aucta Pharmaceuticals, Inc.	2	$37
Dynasplint Systems Inc.	1	$34
Kyowa Kirin, Inc.	2	$32
GE HealthCare	1	$30
Avadel CNS Pharmaceuticals, LLC	1	$29
Impel Pharmaceuticals Inc.	1	$24
Mallinckrodt Hospital Products Inc.	1	$24
Vertical Pharmaceuticals, LLC	1	$21
C2n Diagnostics, LLC	1	$18
Grifols USA, LLC	1	$18
Arbor Pharmaceuticals, Inc.	1	$18
Medtronic	1	$15
Scilex Pharmaceuticals Inc.	1	$13
Collegium Pharmaceutical, Inc.	1	$12

How this compares

Too few neuromusculoskeletal medicine, sports medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$214,937

Medicare patients

817

Services billed

1,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromusculoskeletal medicine, sports medicine in Brooksville

Michael ZiebelmanWinter Haven$42K
Kevin NowickiClermont$7K
David LucasClermont$4K
Raymond WeiandPalm Coast$4K
Larry FishmanBrandon$521
Raul CorreaBradenton$517
Stephen WoodLargo$165
Scott KazdanPembroke Pines$111

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →